Advertisement

Current Diabetes Reports

, 19:53 | Cite as

Bioprinting an Artificial Pancreas for Type 1 Diabetes

  • Juewan Kim
  • Kyungwon Kang
  • Christopher J. Drogemuller
  • Gordon G. Wallace
  • P. Toby CoatesEmail author
Immunology, Transplantation, and Regenerative Medicine (L Piemonti and V Sordi, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Immunology, Transplantation, and Regenerative Medicine

Abstract

Purpose of Review

Pancreatic islet cell transplantation is currently the only curative cell therapy for type 1 diabetes mellitus. However, its potential to treat many more patients is limited by several challenges. The emergence of 3D bioprinting technology from recent advances in 3D printing, biomaterials, and cell biology has provided the means to overcome these challenges.

Recent Findings

3D bioprinting allows for the precise fabrication of complex 3D architectures containing spatially distributed cells, biomaterials (bioink), and bioactive factors. Different strategies to capitalize on this ability have been investigated for the 3D bioprinting of pancreatic islets. In particular, with co-axial bioprinting technology, the co-printability of islets with supporting cells such as endothelial progenitor cells and regulatory T cells, which have been shown to accelerate revascularization of islets and improve the outcome of various transplantations, respectively, has been achieved.

Summary

3D bioprinting of islets for generation of an artificial pancreas is a newly emerging field of study with a vast potential to improve islet transplantation.

Keywords

3D bioprinting Pancreatic islet transplantation Regulatory T cell therapy Endothelial progenitor cell therapy Type 1 diabetes 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Gregory JM, Moore DJ. Type 1 diabetes mellitus. Pediatr Rev 2013.  https://doi.org/10.1016/B978-1-4377-1604-7.00561-3.CrossRefGoogle Scholar
  2. 2.
    Forouhi NG, Wareham NJ. Epidemiology of diabetes. Medicine (Baltimore). 2014;42:698–702.  https://doi.org/10.1383/medc.2006.34.2.57.CrossRefGoogle Scholar
  3. 3.
    Diabetes DOF. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013;36:67–74.  https://doi.org/10.2337/dc13-S067.CrossRefGoogle Scholar
  4. 4.
    Pathiraja V, Kuehlich JP, Campbell PD, Krishnamurthy B, Loudovaris T, Coates PTH, et al. Proinsulin-specific, HLA-DQ8, and HLA-DQ8-transdimer-restricted CD4+ T cells infiltrate islets in type 1 diabetes. Diabetes. 2015;64:172–82.  https://doi.org/10.2337/db14-0858.CrossRefPubMedGoogle Scholar
  5. 5.
    Rezania A, Bruin JE, Arora P, Rubin A, Batushansky I, Asadi A, et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat Biotechnol. 2014;32:1121–33.  https://doi.org/10.1038/nbt.3033.CrossRefPubMedGoogle Scholar
  6. 6.
    Prabakar KR, Domínguez-Bendala J, Damaris Molano R, Pileggi A, Villate S, Ricordi C, et al. Generation of glucose-responsive, insulin-producing cells from human umbilical cord blood-derived mesenchymal stem cells. Cell Transplant. 2012;21:1321–39.  https://doi.org/10.3727/096368911X612530.CrossRefPubMedGoogle Scholar
  7. 7.
    Agarwal A, Brayman KL. Update on islet cell transplantation for type 1 diabetes. Semin Interv Radiol. 2012;29:90–8.  https://doi.org/10.1055/s-0032-1312569.CrossRefGoogle Scholar
  8. 8.
    Robertson RP, Davis C, Larsen J, Stratta R, Sutherland DER, American Diabetes Association. Pancreas and islet transplantation in type 1 diabetes. Diabetes Care. 2006;29:935.  https://doi.org/10.2337/diacare.29.04.06.dc06-9908. CrossRefPubMedGoogle Scholar
  9. 9.
    Chan C, Chim TM, Leung K, Tong C, Wong T, Leung GK. Simultaneous pancreas and kidney transplantation as the standard surgical treatment for diabetes mellitus patients with end-stage renal disease. Hong Kong Med J. 2016;22(1):62–9.  https://doi.org/10.12809/hkmj154613.CrossRefPubMedGoogle Scholar
  10. 10.
    Troppmann C. Complications after pancreas transplantation. Curr Opin Organ Transpl. 2010;15:112–8.  https://doi.org/10.1097/MOT.0b013e3283355349.CrossRefGoogle Scholar
  11. 11.
    Vardanyan M, Parkin E, Gruessner C, Rilo HLR. Pancreas vs. islet transplantation: a call on the future. Curr Opin Organ Transplant. 2010;15:124–30.  https://doi.org/10.1097/MOT.0b013e32833553f8.CrossRefPubMedGoogle Scholar
  12. 12.
    Robertson RP. Islet transplantation as a treatment for diabetes — a work in progress. N Engl J Med. 2004;350:694–705.  https://doi.org/10.1056/NEJMra032425.CrossRefPubMedGoogle Scholar
  13. 13.
    Connell PJO, Holmes-Walker DJ, Goodman D, Hawthorne WJ, Loudovaris T, Gunton JE, et al. Multicenter Australian trial of islet transplantation: improving accessibility and outcomes. Am J Transplant. 2013;13:1850–8.  https://doi.org/10.1002/ajt.12250.CrossRefGoogle Scholar
  14. 14.
    Ichii H, Ricordi C. Current status of islet cell transplantation. J Hepato-Biliary-Pancreat Surg. 2013;16:101–12.  https://doi.org/10.1007/s00534-008-0021-2.Current.CrossRefGoogle Scholar
  15. 15.
    Lacy PE, Walker MM, Fink CJ, Louis S. Perifusion of isolated rat islets in vitro participation of the microtubular system in the biphasic release of insulin. Diabetes. 1972;21:987–98.  https://doi.org/10.2337/diab.21.10.987.CrossRefPubMedGoogle Scholar
  16. 16.
    Najarian JS, Sutherland DER, Baumgartner D, Burke B, Rynasiewicz JJ, Matas AJ, et al. Total or near total pancreatectomy and islet autotransplantation for treatment of chronic pancreatitis.pdf. Ann Surg. 1980;192:526–42.CrossRefGoogle Scholar
  17. 17.
    Robertson RP, Lanz KJ, Sutherland DER, Kendall DM. Prevention of diabetes for up to 13 years by autoislet transplantation after pancreatectomy for chronic pancreatitis. Diabetes. 2001;50:48–50.  https://doi.org/10.2337/diabetes.50.1.47.CrossRefGoogle Scholar
  18. 18.
    Shapiro AMJ, Lakey JRT, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocoricoid-free imunosuppressive regimen. N Engl J Med. 2000;343:230–8.  https://doi.org/10.1056/NEJM200007273430401.CrossRefPubMedGoogle Scholar
  19. 19.
    Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005;54:2060–9.CrossRefGoogle Scholar
  20. 20.
    Leitão CB, Cure P, Tharvanji T, Baidal DA, Alejandro R. Current challenges in islet transplantation. Curr Diab Rep. 2008;8:324–31.  https://doi.org/10.1007/s11892-008-0057-3.CrossRefPubMedGoogle Scholar
  21. 21.
    Rheinheimer J, Bauer AC, Silveiro SP, Estivalet AAF, Bouças AP, Rosa AR, et al. Human pancreatic islet transplantation: an update and description of the establishment of a pancreatic islet isolation laboratory. Arch Endocrinol Metab. 2015;59:161–70.  https://doi.org/10.1590/2359-3997000000030.CrossRefPubMedGoogle Scholar
  22. 22.
    Lacy PE, Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes. 1967;16:35–9.  https://doi.org/10.2337/diab.16.1.35.CrossRefPubMedGoogle Scholar
  23. 23.
    Carlsson PO, Palm F, Andersson A, Liss P. Markedly decreased oxygen tension in transplanted rat pancreatic islets irrespective of the implantation site. Diabetes. 2001;50:489–95.  https://doi.org/10.2337/diabetes.50.3.489.CrossRefPubMedGoogle Scholar
  24. 24.
    Bennet W, Sundberg B, Groth CG, Brendel MD, Brandhorst D, Brandhorst H, et al. Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes. 1999;48:1907–14.  https://doi.org/10.2337/diabetes.48.10.1907.CrossRefPubMedGoogle Scholar
  25. 25.
    Moberg L, Johansson H, Lukinius A, Berne C, Foss A, Källen R, et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet. 2002;360:2039–45.  https://doi.org/10.1016/S0140-6736(02)12020-4.CrossRefPubMedGoogle Scholar
  26. 26.
    Van Der Windt DJ, Bottino R, Casu A, Campanile N, Cooper DKC. Rapid loss of intraportally transplanted islets: an overview of pathophysiology and preventive strategies. Xenotransplantation. 2007;14:288–97.  https://doi.org/10.1111/j.1399-3089.2007.00419.x.CrossRefPubMedGoogle Scholar
  27. 27.
    Cantarelli E, Piemonti L. Alternative transplantation sites for pancreatic islet grafts. Curr Diab Rep. 2011;11:364–74.  https://doi.org/10.1007/s11892-011-0216-9.CrossRefPubMedGoogle Scholar
  28. 28.
    Bennet W, Groth CG, Larsson R, Nilsson B, Korsgren O. Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Ups J Med Sci. 2000;105:125–33.  https://doi.org/10.1517/03009734000000059.CrossRefPubMedGoogle Scholar
  29. 29.
    Margolis RN, Holup JJ, Selawry HP. Effects of intratesticular islet transplantation on hepatic glycogen metabolism in the rat. Diabetes Res Clin Pract. 1986;2:291–9.  https://doi.org/10.1016/S0168-8227(86)80006-7.CrossRefPubMedGoogle Scholar
  30. 30.
    Ar’Rajab A, Dawidson IJ, Harris RB, Sentementes JT. Immune privilege of the testis for islet xenotransplantation (rat to mouse). Cell Transplant. 2017;3:493–8.  https://doi.org/10.1177/096368979400300606.CrossRefGoogle Scholar
  31. 31.
    Kemp CB, Knight MJ, Scharp DW, Ballinger WF, Lacy PE. Effect of transplantation site on the results of pancreatic islet isografts in diabetic rats. Diabetologia. 1973;9:486–91.  https://doi.org/10.1007/BF00461694.CrossRefPubMedGoogle Scholar
  32. 32.
    Melzi R, Sanvito F, Mercalli A, Andralojc K, Bonifacio E, Piemonti L. Intrahepatic islet transplant in the mouse: functional and morphological characterization. Cell Transplant. 2008;17:1361–70.  https://doi.org/10.3727/096368908787648146.CrossRefPubMedGoogle Scholar
  33. 33.
    Mao G, Chen G, Bai H, Song T, Wang Y. The reversal of hyperglycaemia in diabetic mice using PLGA scaffolds seeded with islet-like cells derived from human embryonic stem cells. Biomaterials. 2009;30:1706–14.  https://doi.org/10.1016/j.biomaterials.2008.12.030.CrossRefPubMedGoogle Scholar
  34. 34.
    De Vos P, Hamel AF, Tatarkiewicz K. Considerations for successful transplantation of encapsulated pancreatic islets. Diabetologia. 2002;45:159–73.  https://doi.org/10.1007/s00125-001-0729-x.CrossRefPubMedGoogle Scholar
  35. 35.
    Mallett AG, Korbutt GS. Alginate modification improves long-term survival and function of transplanted encapsulated islets. Tissue Eng Part A. 2009;15:1301–9.  https://doi.org/10.1089/ten.tea.2008.0118.CrossRefPubMedGoogle Scholar
  36. 36.
    Desai T, Shea LD. Advances in islet encapsulation technologies. Nat Rev Drug Discov. 2017;16:338–50.  https://doi.org/10.1038/nrd.2016.232.CrossRefPubMedGoogle Scholar
  37. 37.
    Vériter S, Mergen J, Goebbels R-M, Aouassar N, Grégoire C, Jordan B, et al. In vivo selection of biocompatible alginates for islet encapsulation and subcutaneous transplantation. Tissue Eng Part A. 2010;16:1503–13.  https://doi.org/10.1089/ten.TEA.2009.0286.CrossRefPubMedGoogle Scholar
  38. 38.
    Lum ZP, Tai IT, Krestow M, Norton J, Vacek I, Sun AM. Prolonged reversal of diabetic state in NOD mice by xenografts of microencapsulated rat islets. Diabetes. 1991;40:1511–6.  https://doi.org/10.2337/diab.40.11.1511.CrossRefPubMedGoogle Scholar
  39. 39.
    Cui W, Barr G, Faucher KM, Sun X-L, Safley SA, Weber CJ, et al. A membrane-mimetic barrier for islet encapsulation. Transplant Proc. 2004;36:1206–8.  https://doi.org/10.1016/j.transproceed.2004.04.059.CrossRefPubMedGoogle Scholar
  40. 40.
    Lamb M, Storrs R, Li S, Liang O, Laugenour K, Dorian R, et al. Function and viability of human islets encapsulated in alginate sheets: in vitro and in vivo culture. Transplant Proc. 2011;43:3265–6.  https://doi.org/10.1016/j.transproceed.2011.10.028.CrossRefPubMedGoogle Scholar
  41. 41.
    Zhi ZL, Kerby A, King AJF, Jones PM, Pickup JC. Nano-scale encapsulation enhances allograft survival and function of islets transplanted in a mouse model of diabetes. Diabetologia. 2012;55:1081–90.  https://doi.org/10.1007/s00125-011-2431-y.CrossRefPubMedGoogle Scholar
  42. 42.
    Ma M, Chiu A, Sahay G, Doloff JC, Dholakia N, Thakrar R, et al. Core-shell hydrogel microcapsules for improved islets encapsulation. Adv Healthc Mater. 2013;2:667–72.  https://doi.org/10.1002/adhm.201200341.CrossRefPubMedGoogle Scholar
  43. 43.
    Hobbs HA, Kendall WF, Darrabie M, Opara EC. Prevention of morphological changes in alginate microcapsules for islet xenotransplantation. J Investig Med. 2001;49:572–5.  https://doi.org/10.2310/6650.2001.33722.CrossRefPubMedGoogle Scholar
  44. 44.
    De Vos P, Hillebrands JL, De Haan BJ, Strubbe JH, Van Schilfgaarde R. Efficacy of a prevascularized expanded polytetrafluoroethylene solid support system as a transplantation site for pancreatic islets. Transplantation. 1997;63:824–30.  https://doi.org/10.1097/00007890-199703270-00006.CrossRefPubMedGoogle Scholar
  45. 45.
    Dufour JM, Rajotte RV, Zimmerman M, Rezania A, Kin T, Dixon DE, et al. Development of an ectopic site for islet transplantation, using biodegradable scaffolds. Tissue Eng. 2005;11:1323–31.  https://doi.org/10.1089/ten.2005.11.1323.CrossRefPubMedGoogle Scholar
  46. 46.
    Wang RN, Rosenberg L. Maintenance of beta-cell function and survival following islet isolation requires re-establishment of the islet-matrix relationship. J Endocrinol. 1999;163:181–90.  https://doi.org/10.1677/joe.0.1630181.CrossRefPubMedGoogle Scholar
  47. 47.
    Gibly RF, Zhang X, Graham ML, Hering BJ, Kaufman DB, Lowe WL, et al. Extrahepatic islet transplantation with microporous polymer scaffolds in syngeneic mouse and allogeneic porcine models. Biomaterials. 2011;32:9677–84.  https://doi.org/10.1016/j.biomaterials.2011.08.084.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Berman DM, O’Neil JJ, Coffey LCK, Chaffanjon PCJ, Kenyon NM, Ruiz P, et al. Long-term survival of nonhuman primate islets implanted in an omental pouch on a biodegradable scaffold. Am J Transplant. 2009;9:91–104.  https://doi.org/10.1111/j.1600-6143.2008.02489.x.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Blomeier H, Zhang X, Rives C, Brissova M, Hughes E, Baker M, et al. Polymer scaffolds as synthetic microenvironments for extrahepatic islet transplantation. Transplantation. 2006;82:452–9.  https://doi.org/10.1097/01.tp.0000231708.19937.21.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Murphy SV, Atala A. 3D bioprinting of tissues and organs. Nat Biotechnol. 2014;32:773–85.  https://doi.org/10.1038/nbt.2958.CrossRefPubMedGoogle Scholar
  51. 51.
    Schubert C, van Langeveld MC, Donoso LA. Innovations in 3D printing: a 3D overview from optics to organs. Br J Ophthalmol. 2014;98:159–61.  https://doi.org/10.1136/bjophthalmol-2013-304446.CrossRefPubMedGoogle Scholar
  52. 52.
    Ozbolat IT, Chen H, Yu Y. Development of ‘multi-arm bioprinter’ for hybrid biofabrication of tissue engineering constructs. Robot Comput Integr Manuf. 2014;30:295–304.  https://doi.org/10.1016/j.rcim.2013.10.005.CrossRefGoogle Scholar
  53. 53.
    Kolesky DB, Truby RL, Gladman AS, Busbee TA, Homan KA, Lewis JA. 3D bioprinting of vascularized, heterogeneous cell-laden tissue constructs. Adv Mater. 2014;26:3124–30.  https://doi.org/10.1002/adma.201305506.CrossRefPubMedGoogle Scholar
  54. 54.
    Poldervaart MT, Gremmels H, van Deventer K, Fledderus JO, Oner FC, Verhaar MC, et al. Prolonged presence of VEGF promotes vascularization in 3D bioprinted scaffolds with defined architecture. J Control Release. 2014;184:58–66.  https://doi.org/10.1016/j.jconrel.2014.04.007.CrossRefPubMedGoogle Scholar
  55. 55.
    Yue Z, Liu X, Coates PT, Wallace GG. Advances in printing biomaterials and living cells. Curr Opin Organ Transplant. 2016;21:467–75.  https://doi.org/10.1097/MOT.0000000000000346.CrossRefPubMedGoogle Scholar
  56. 56.
    Di Bella C, Duchi S, O’Connell CD, Blanchard R, Augustine C, Yue Z, et al. In situ handheld three-dimensional bioprinting for cartilage regeneration. J Tissue Eng Regen Med. 2018;12:611–21.  https://doi.org/10.1002/term.2476.CrossRefPubMedGoogle Scholar
  57. 57.
    Kesti M, Eberhardt C, Pagliccia G, Kenkel D, Grande D, Boss A, et al. Bioprinting complex cartilaginous structures with clinically compliant biomaterials. Adv Funct Mater. 2015;25:7406–17.  https://doi.org/10.1002/adfm.201503423.CrossRefGoogle Scholar
  58. 58.
    Lee JW, Choi Y-J, Yong W-J, Pati F, Shim J-H, Kang KS, et al. Development of a 3D cell printed construct considering angiogenesis for liver tissue engineering. Biofabrication. 2016;8:015007.  https://doi.org/10.1088/1758-5090/7/2/025009.CrossRefPubMedGoogle Scholar
  59. 59.
    Gu Q, Tomaskovic-crook E, Lozano R, Chen Y, Kapsa RM, Zhou Q, et al. Functional 3D neural mini-tissues from printed gel-based bioink and human neural stem cells. Adv Healthc Mater. 2016;5:1429–38.  https://doi.org/10.1002/adhm.201600095.CrossRefPubMedGoogle Scholar
  60. 60.
    Derakhshanfar S, Mbeleck R, Xu K, Zhang X, Zhong W, Xing M. 3D bioprinting for biomedical devices and tissue engineering: a review of recent trends and advances. Bioact Mater Elsevier Ltd. 2018;3:144–56.  https://doi.org/10.1016/j.bioactmat.2017.11.008.CrossRefGoogle Scholar
  61. 61.
    •• Marchioli G, Van Gurp L, Van Krieken PP, Stamatialis D, Engelse M, Van Blitterswijk CA, et al. Fabrication of three-dimensional bioplotted hydrogel scaffolds for islets of Langerhans transplantation. Biofabrication. 2015;7:025009.  https://doi.org/10.1088/1758-5090/7/2/025009 3D bioprinting technology was used to print pancreatic islets using alginate-based bioinks. 3D bioprinted human islets were highly viable and morphologically sound. CrossRefPubMedGoogle Scholar
  62. 62.
    •• Duin S, Schütz K, Ahlfeld T, Lehmann S, Lode A, Ludwig B, et al. 3D bioprinting of functional islets of Langerhans in an alginate/methylcellulose hydrogel blend. Adv Healthc Mater. 2019;1801631:1–14.  https://doi.org/10.1002/adhm.201801631 3D bioprinting technology was used to print rat islets using an alginate/methylcellulose bioink with minimal impact on islet viability , morphology, and function. CrossRefGoogle Scholar
  63. 63.
    Penko D, Mohanasundaram D, Sen S, Mee C, Bonder CS, Coates PTH, et al. Incorporation of endothelial progenitor cells into mosaic pseudoislets. Islets. 2011;3:73–9.  https://doi.org/10.4161/isl.3.3.15392.CrossRefPubMedGoogle Scholar
  64. 64.
    •• Liu X, Carter SSD, Renes MJ, Kim J, Rojas-Canales DM, Penko D, et al. Development of a coaxial 3D printing platform for biofabrication of implantable islet-containing constructs. Adv Healthc Mater. 2019;8(7):e1801181.  https://doi.org/10.1002/adhm.201801181 A co-axial bioprinter was developed in-house and alginate-gelatin methacryloyl bioink was formulated, for co-printing of islets with supporting cells such as endothelial progenitor cells and regulatory T cells. Co-printed mouse islets and endothelial progenitor cells were highly viable. CrossRefPubMedGoogle Scholar
  65. 65.
    Lifson N, Lassa CV, Dixit PK. Relation between blood flow and morphology in islet organ of rat pancreas. Am J Phys. 1985;249:E43–8.  https://doi.org/10.1152/ajpendo.1985.249.1.E43.CrossRefGoogle Scholar
  66. 66.
    Johansson A, Lau J, Sandberg M, Borg LAH, Magnusson PU, Carlsson P-O. Endothelial cell signalling supports pancreatic beta cell function in the rat. Diabetologia. 2009;52:2385–94.  https://doi.org/10.1007/s00125-009-1485-6.CrossRefPubMedGoogle Scholar
  67. 67.
    Davalli AM, Scaglia L, Zangen DH, Hollister J, Bonner-Weir S, Weir GC. Vulnerability of islets in the immediate posttransplantation period. Dynamic changes in structure and function. Diabetes. 1996;45:1161–7.  https://doi.org/10.2337/diabetes.45.9.1161.CrossRefPubMedGoogle Scholar
  68. 68.
    de Groot M, Schuurs T, Fekken S, Leuvenink H, van Schilfgaarde R, Keizer J. Response of encapsulated rat pancreatic islets to hypoxia. Cell Transplant. 2003;12:867–75.  https://doi.org/10.3727/000000003771000219.CrossRefPubMedGoogle Scholar
  69. 69.
    Campbell PD, Weinberg A, Chee J, Mariana L, Ayala R, Hawthorne WJ, et al. Expression of pro- and antiapoptotic molecules of the Bcl-2 family in human islets postisolation. Cell Transplant. 2012;21:49–60.  https://doi.org/10.3727/096368911X566262.CrossRefPubMedGoogle Scholar
  70. 70.
    Cantley J, Walters SN, Jung M, Weinberg A, Cowley MJ, Whitworth PT, et al. A preexistent hypoxic gene signature predicts impaired islet graft function and glucose homeostasis. Cell Transplant. 2013;22:2147–59.  https://doi.org/10.3727/096368912X658728.CrossRefPubMedGoogle Scholar
  71. 71.
    Vajkoczy P, Menger MD, Simpson E, Messmer K. Angiogenesis and vascularization of murine pancreatic islet isografts. Transplantation. 1995;60:123–7.  https://doi.org/10.1097/00007890-199507000-00002.CrossRefPubMedGoogle Scholar
  72. 72.
    Mattsson G, Jansson L, Carlsson P-O. Decreased vascular density in mouse pancreatic islets after transplantation. Diabetes. 2002;51:1362–6.  https://doi.org/10.2337/diabetes.51.5.1362.CrossRefPubMedGoogle Scholar
  73. 73.
    Cho H-J, Lee N, Lee JY, Choi YJ, Ii M, Wecker A, et al. Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart. J Exp Med. 2007;204:3257–69.  https://doi.org/10.1084/jem.20070166.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med. 2003;9:702–12.  https://doi.org/10.1038/nm0603-702.CrossRefPubMedGoogle Scholar
  75. 75.
    Peiris HS, Bonder CS, Coates PT, Keating DJ, Jessup CF. The b-cell/EC axis: how do islet cells talk to each other? Diabetes Care. 2014;63:3–11.  https://doi.org/10.2337/db13-0617.CrossRefGoogle Scholar
  76. 76.
    Kang S, Park HS, Jo A, Hong SH, Lee HN, Lee YY, et al. Endothelial progenitor cell cotransplantation enhances islet engraftment by rapid revascularization. Diabetes. 2012;61:866–76.  https://doi.org/10.2337/db10-1492.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Quaranta P, Antonini S, Spiga S, Mazzanti B, Curcio M, Mulas G, et al. Co-transplantation of endothelial progenitor cells and pancreatic islets to induce long-lasting normoglycemia in streptozotocin-treated diabetic rats. PLoS One. 2014;9:1–13.  https://doi.org/10.1371/journal.pone.0094783.CrossRefGoogle Scholar
  78. 78.
    • Penko D, Rojas-Canales D, Mohanasundaram D, Peiris HS, Sun WY, Drogemuller CJ, et al. Endothelial progenitor cells enhance islet engraftment, influence beta cell function and modulate islet connexin 36 expression. Cell Transplant. 2015;24:37–48.  https://doi.org/10.3727/096368913X673423 Co-transplantation of endothelial progenitor cells with pancreatic islets enhanced islet engraftment by improving the cure rate and the glucose control. CrossRefPubMedGoogle Scholar
  79. 79.
    Golshayan D, Pascual M. Tolerance-inducing immunosuppressive strategies in clinical transplantation. Drugs. 2008;68:2113–30.  https://doi.org/10.1016/S0140-6736(98)07493-5.CrossRefPubMedGoogle Scholar
  80. 80.
    Xing Y, Hogquist KA. T-cell tolerance: central and peripheral. Cold Spring Harb Perspect Biol 2012;1–16.Google Scholar
  81. 81.
    Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10:490–500.  https://doi.org/10.1038/nri2785.CrossRefPubMedGoogle Scholar
  82. 82.
    Tang Q, Bluestone JA. Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med. 2013;3:1–15.  https://doi.org/10.1101/cshperspect.a015552.CrossRefGoogle Scholar
  83. 83.
    Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8:523–32.  https://doi.org/10.1038/nri2343.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Cunningham EC, Sharland AF, Alex Bishop G. Liver transplant tolerance and its application to the clinic: can we exploit the high dose effect? Clin Dev Immunol. 2013;2013:1–9.  https://doi.org/10.1155/2013/419692.CrossRefGoogle Scholar
  85. 85.
    Cippà PE, Fehr T. Spontaneous tolerance in kidney transplantation - an instructive, but very rare paradigm. Transpl Int. 2011;24:534–5.  https://doi.org/10.1111/j.1432-2277.2011.01260.x.CrossRefPubMedGoogle Scholar
  86. 86.
    Orlando G, Hematti P, Stratta R, Burke G, Di Cocco P, Pisani F, et al. Clinical operational tolerance after renal transplantation. Ann Surg. 2010;252:915–28.  https://doi.org/10.1038/nbt.3121.ChIP-nexus.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Li W, Kuhr CS, Zheng XX, Carper K, Thomson AW, Reyes JD, et al. New insights into mechanisms of spontaneous liver transplant tolerance: the role of Foxp3-expressing CD25+CD4+ regulatory T cells. Am J Transplant. 2008;8:1639–51.  https://doi.org/10.1111/j.1600-6143.2008.02300.x.CrossRefPubMedGoogle Scholar
  88. 88.
    Heidt S, Wood KJ. Biomarkers of operational tolerance in solid organ transplantation. Expert Opin Med Diagn. 2012;6:281–93.  https://doi.org/10.1517/17530059.2012.680019.BIOMARKERS.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Niemann N, Sawitzki B. Treg therapy in transplantation: how and when will we do it ? Curr Transplant Reports. 2015;2:233–41.  https://doi.org/10.1007/s40472-015-0066-5.CrossRefGoogle Scholar
  90. 90.
    Riley JL, June CH, Blazar BR. Human T regulatory cells as therapeutic agents: take a billion or so of these and call me in the morning. Immunity. 2010;30:656–65.  https://doi.org/10.1016/j.immuni.2009.04.006.Human.CrossRefGoogle Scholar
  91. 91.
    McMurchy AN, Bushell A, Levings MK, Wood KJ. Moving to tolerance: clinical application of T regulatory cells. Semin Immunol. 2011;23:304–13.  https://doi.org/10.1016/j.smim.2011.04.001.CrossRefPubMedGoogle Scholar
  92. 92.
    Xiao F, Ma L, Zhao M, Huang G, Mirenda V, Dorling A, et al. Ex vivo expanded human regulatory T cells delay islet allograft rejection via inhibiting islet-derived monocyte chemoattractant protein-1 production in CD34+ stem cells-reconstituted NOD-scid IL2rgnull mice. PLoS One. 2014;9:1–12.  https://doi.org/10.1371/journal.pone.0090387.CrossRefGoogle Scholar
  93. 93.
    Wu DC, Hester J, Nadig SN, Zhang W, Trzonkowski P, Gray D, et al. Ex vivo expanded human regulatory T cells can prolong survival of a human islet allograft in a humanized mouse model. Transplantation. 2013;96:707–16.  https://doi.org/10.1097/TP.0b013e31829fa271.CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    • Chandran S, Tang Q, Sarwal M, Polyclonal Regulatory T. Cell therapy for control of inflammation in kidney transplants. Am J Transplant. 2017;17:2945–54.  https://doi.org/10.1111/ajt.14415 Infusion of ex vivo expanded regulatory T cells was well tolerated with no adverse effects in kidney transplant recipients. CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    • Todo S, Yamashita K, Goto R, Zaitsu M, Nagatsu A, Oura T, et al. A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation. Hepatology. 2016;64:632–43.  https://doi.org/10.1002/hep.28459 Infusion of ex vivo expanded regulatory T cells was well tolerated with no adverse effects in liver transplant recipients. Seven patients have been maintaining normal graft function without the use of immunosuppressive drugs for more than 16 months. CrossRefPubMedGoogle Scholar
  96. 96.
    Ackermann AM, Gannon M. Molecular regulation of pancreatic beta-cell mass development, maintenance, and expansion. J Mol Endocrinol. 2007;38:193–206.  https://doi.org/10.1677/JME-06-0053.CrossRefPubMedGoogle Scholar
  97. 97.
    Hughes A, Rojas-canales D, Drogemuller C. IGF2: an endocrine hormone to improve islet transplant survival. J Endocrinol. 2014;221:R41–8.  https://doi.org/10.1530/JOE-13-0557.CrossRefPubMedGoogle Scholar
  98. 98.
    Reik W, Sun F-L, Dean WL, Kelsey G, Allen ND. Transactivation of Igf2 in a mouse model of Beckwith-Wiedemann syndrome. Nature. 1997;389:809–15.  https://doi.org/10.1038/39797.CrossRefPubMedGoogle Scholar
  99. 99.
    Petrik J, Arany E, McDonald TJ, Hill DJ. Apoptosis in the pancreatic islet cells of the neonatal rat is associated with a reduced expression of insulin-like growth factor II that may act as a survival factor. Endocrinology. 1998;139:2994–3004.  https://doi.org/10.1210/endo.139.6.6042.CrossRefPubMedGoogle Scholar
  100. 100.
    Hill DJ, Strutt B, Arany E, Zaina S, Coukell S, Graham CF. Increased and persistent circulating insulin-like growth factor II in neonatal transgenic mice suppresses developmental apoptosis in the pancreatic islets. Endocrinology. 2000;141:1151–7.  https://doi.org/10.1210/endo.141.3.7354.CrossRefPubMedGoogle Scholar
  101. 101.
    Hogg J, Han VK, Clemmons DR, Hill DJ. Interactions of nutrients, insulin-like growth factors (IGFs) and IGF-binding proteins in the regulation of DNA synthesis by isolated fetal rat islets of Langerhans. J Endocrinol. 1993;138:401–12.  https://doi.org/10.1677/joe.0.1380401.CrossRefPubMedGoogle Scholar
  102. 102.
    Robitaille R, Dusseault J, Henley N, Rosenberg L, Hallé J-P. Insulin-like growth factor II allows prolonged blood glucose normalization with a reduced islet cell mass transplantation. Endocrinology. 2003;144:3037–45.  https://doi.org/10.1210/en.2002-0185.CrossRefPubMedGoogle Scholar
  103. 103.
    Petrik J, Reusens B, Arany E, Remacle C, Coelho C, Hoet JJ, et al. A low protein diet alters the balance of islet cell replication and apoptosis in the fetal and neonatal rat and is associated with a reduced pancreatic expression of insulin-like growth factor-II. Endocrinology. 1999;140:4861–73.  https://doi.org/10.1210/endo.140.10.7042.CrossRefPubMedGoogle Scholar
  104. 104.
    Hughes A, Mohanasundaram D, Kireta S, Jessup CF, Drogemuller CJ, Coates PTH. Insulin-like growth factor-II (IGF-II) prevents proinflammatory cytokine-induced apoptosis and significantly improves islet survival after transplantation. Transp J. 2013;95:671–8.  https://doi.org/10.1097/TP.0b013e31827fa453.CrossRefGoogle Scholar
  105. 105.
    Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes and Cancer. 2011;2:1097–105.  https://doi.org/10.1177/1947601911423031.CrossRefPubMedGoogle Scholar
  106. 106.
    Lammert E, Gu G, Mclaughlin M, Brown D, Brekken R, Murtaugh LC, et al. Role of VEGF-A in vascularization of pancreatic islets. Curr Biol. 2003;13:1070–4.  https://doi.org/10.1016/S0960-9822(03)00378-6.CrossRefPubMedGoogle Scholar
  107. 107.
    Witkowski P, Sondermeijer H, Hardy MA, Woodland DC, Lee K, Bhagat G, et al. Islet grafting and imaging in a bioengineered intramuscular space. Transplantation. 2009;88:1065–74.  https://doi.org/10.1097/TP.0b013e3181ba2e87.CrossRefPubMedPubMedCentralGoogle Scholar
  108. 108.
    • Marchioli G, Di Luca A, De Koning E, Engelse M, Van Blitterswijk CA, Karperien M, et al. Hybrid polycaprolactone/alginate scaffolds functionalized with VEGF to promote de novo vessel formation for the transplantation of islets of Langerhans. Adv Healthc Mater. 2016;5:1606–16.  https://doi.org/10.1002/adhm.201600058 Polycaprolactone scaffold functionalized with VEGF promoted vascularization and improved function of encapsulated islets embedded within the polycaprolactone scaffold. CrossRefPubMedGoogle Scholar
  109. 109.
    Boyman O, Sprent J. The role of interleukin - 2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12:180–90.  https://doi.org/10.1038/nri3156.CrossRefPubMedGoogle Scholar
  110. 110.
    Sakaguchi S, Takahashi T, Nishizuka Y. Study on cellular events in post-thymectomy autoimmune oophoritis in mice. J Exp Med. 1982;156:1577–86.CrossRefGoogle Scholar
  111. 111.
    Chinen T, Kannan AK, Levine AG, Fan X, Klein U, Zheng Y, et al. An essential role for IL-2 receptor in regulatory T cell function Takatoshi. Nat Immunol. 2016;17:1322–33.  https://doi.org/10.1038/ni.3540.CrossRefPubMedPubMedCentralGoogle Scholar
  112. 112.
    Létourneau S, Krieg C, Pantaleo G, Boyman O. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J Allergy Clin Immunol. 2009;123:758–62.  https://doi.org/10.1016/j.jaci.2009.02.011.CrossRefPubMedGoogle Scholar
  113. 113.
    Sadlon TJ, Wilkinson BG, Pederson S, Brown CY, Bresatz S, Gargett T, et al. Genome-wide identification of human FOXP3 target genes in natural regulatory T cells. J Immunol. 2010;185:1071–81.  https://doi.org/10.4049/jimmunol.1000082.CrossRefPubMedGoogle Scholar
  114. 114.
    Beyer M, Thabet Y, Müller R, Sadlon T, Classen S, Lahl K, et al. Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat Immunol. 2011;12:898–907.  https://doi.org/10.1038/ni.2084.CrossRefPubMedPubMedCentralGoogle Scholar
  115. 115.
    Whitehouse G, Gray E, Mastoridis S, Merritt E, Kodela E, Yang JHM. IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors. Proc Natl Acad Sci USA. 2017;114:7083–8.  https://doi.org/10.1073/pnas.1620835114.CrossRefPubMedGoogle Scholar
  116. 116.
    Shevach EM. Application of IL-2 therapy to target T regulatory cell function. Trends Immunol. 2013;33:626–32.  https://doi.org/10.1016/j.it.2012.07.007.CrossRefGoogle Scholar
  117. 117.
    Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, et al. IL-2 regulates FOXP3 expression in human CD4+ CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 2006;108:1571–80.  https://doi.org/10.1182/blood-2006-02-004747.CrossRefPubMedPubMedCentralGoogle Scholar
  118. 118.
    Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365:2055–66.  https://doi.org/10.1056/NEJMoa1108188.CrossRefPubMedPubMedCentralGoogle Scholar
  119. 119.
    Matsuoka K, Koreth J, Kim HT, Bascug OG, Kawano Y, Murase K, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5:179ra43.  https://doi.org/10.1126/scitranslmed.3005265.CrossRefPubMedPubMedCentralGoogle Scholar
  120. 120.
    Koreth J, Kim HT, Jones KT, Lange PB, Reynolds CG, Chammas MJ, et al. Efficacy , durability , and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood. 2016;128:130–8.  https://doi.org/10.1182/blood-2016-02-702852.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Juewan Kim
    • 1
  • Kyungwon Kang
    • 2
  • Christopher J. Drogemuller
    • 2
    • 3
  • Gordon G. Wallace
    • 4
  • P. Toby Coates
    • 2
    • 3
    Email author
  1. 1.Department of Molecular & Cellular Biology, School of Biological SciencesThe University of AdelaideAdelaideAustralia
  2. 2.Discipline of Medicine, School of MedicineThe University of AdelaideAdelaideAustralia
  3. 3.Central Northern Adelaide Renal and Transplantation Service (CNARTS)The Royal Adelaide HospitalAdelaideAustralia
  4. 4.Intelligent Polymer Research Institute, ARC Centre of Excellence for Electromaterial ScienceUniversity of WollongongWollongongAustralia

Personalised recommendations